1. High expression of AK1 predicts inferior prognosis in acute myeloid leukemia patients undergoing chemotherapy
- Author
-
Hongmian Zhao, Yunli Shao, Ning Hu, Yijie Zhang, Jinlong Shi, Lin Fu, and Tong Qin
- Subjects
0301 basic medicine ,Adenylate kinase 1 ,Oncology ,Male ,Time Factors ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,chemotherapy ,Biochemistry ,0302 clinical medicine ,Risk Factors ,hemic and lymphatic diseases ,Research Articles ,Cancer ,Aged, 80 and over ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,Genomics ,Middle Aged ,Progression-Free Survival ,Up-Regulation ,Leukemia, Myeloid, Acute ,030220 oncology & carcinogenesis ,Female ,AK1 ,Adult ,medicine.medical_specialty ,Prognostic factor ,Adolescent ,Clinical Decision-Making ,Biophysics ,Antineoplastic Agents ,acute myeloid leukemia ,Risk Assessment ,03 medical and health sciences ,Young Adult ,Internal medicine ,Cancer genome ,medicine ,Biomarkers, Tumor ,Humans ,In patient ,allogeneic hematopoietic stem cell transplantation ,Molecular Biology ,Aged ,Retrospective Studies ,Chemotherapy ,business.industry ,Adenylate Kinase ,Cell Biology ,030104 developmental biology ,Mutation ,prognosis ,business ,Chemotherapy group - Abstract
The purpose of the present study was to investigate whether expression levels of adenylate kinase 1 (AK1) were associated with prognosis of acute myeloid leukemia (AML) in patients treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). 85 AML patients with AK1 expression report who received chemotherapy-alone and 71 who underwent allo-HSCT from The Cancer Genome Atlas database were identified and grouped into either AK1high or AK1low based on their AK1 expression level relative to the median. Then, overall survival (OS) and event-free survival (EFS) were compared between patients with high vs. low AK1 expression. In the chemotherapy group, high AK1 expression was favorable for both EFS (P=0.016) and OS (P=0.014). In the allo-HSCT group, there was no association for AK1 expression levels and clinical outcomes. Further analyses suggested that in the high AK1 expression group, EFS and OS were longer in patients treated with allo-HSCT compared with those treated with chemotherapy (P=0.0011; P
- Published
- 2020